Entrada Therapeutics, Inc.

TRDA

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001689375

SEC filings (opens in a new tab)

In the last 90 days, Entrada Therapeutics, Inc. insiders filed 0 open-market purchases and 7 sales; 128 institutions reported holding it in 13F filings for Q2 2026, worth $214.4M in total; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding Entrada Therapeutics, Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022 All holders in Q3 2022

13F holders of TRDA: Q3 2022 compared with Q4 2022
Measure	Q3 2022	Q4 2022	Change
Holders	33	47	+14
Shares	24.5M	24.7M	+198.6K (+0.8%)
Value	$386.4M	$334.2M	−$52.2M (−13.5%)

New holders (17)

Institutions that held Entrada Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to TRDA in Q4 2022
Institution	Shares	Value	% of portfolio
Susquehanna International Group, LLP	111,797	$1.51M	0.00%
Millennium Management LLC	39,894	$539.0K	0.00%
Swiss National Bank	26,500	$358.3K	0.00%
Natixis	26,186	$354.0K	0.00%
Qube Research & Technologies Ltd	16,782	$226.9K	0.00%
Jane Street Group, LLC	14,524	$196.4K	0.00%
Ergoteles LLC	14,019	$189.5K	0.01%
Bank of New York Mellon Corp	12,439	$168.2K	0.00%
Balyasny Asset Management LLC	12,132	$164.0K	0.00%
State of Wisconsin Investment Board	10,971	$148.3K	0.00%
683 Capital Management, LLC	10,355	$140.0K	0.01%
California State Teachers Retirement System	9,514	$128.6K	0.00%
Credit Suisse AG	8,811	$119.1K	0.00%
JPMorgan Chase & Co	7,593	$103.0K	0.00%
Legal & General Group Plc	2,937	$39.7K	0.00%
UBS Group AG	1,257	$17.0K	0.00%
Royal Bank of Canada	28	$0	0.00%

Sold out (3)

Institutions that held Entrada Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.

Institutions that sold out of TRDA in Q4 2022
Institution	Shares, Q3 2022	Value, Q3 2022
Invesco Ltd.	95,209	$1.50M
Fred Alger Management, LLC	17,955	$283.0K
BNP Paribas Arbitrage, SA	198	$3.12K